BeiGene Change in Accounts Receivable 2014-2024 | ONC
BeiGene annual/quarterly change in accounts receivable history and growth rate from 2014 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- BeiGene change in accounts receivable for the quarter ending September 30, 2024 was $-0.204B, a 41.97% increase year-over-year.
- BeiGene change in accounts receivable for the twelve months ending September 30, 2024 was $-0.646B, a 499.18% increase year-over-year.
- BeiGene annual change in accounts receivable for 2023 was $-0.188B, a 161.92% decline from 2022.
- BeiGene annual change in accounts receivable for 2022 was $0.304B, a 171.89% decline from 2021.
- BeiGene annual change in accounts receivable for 2021 was $-0.423B, a 4182.01% decline from 2020.
BeiGene Annual Change in Accounts Receivable
(Millions of US $) |
| 2023 |
$-188 |
| 2022 |
$304 |
| 2021 |
$-423 |
| 2020 |
$10 |
| 2019 |
$-30 |
| 2018 |
$-12 |
| 2017 |
$-29 |
| 2016 |
$ |
| 2015 |
$ |
| 2014 |
$ |
| 2013 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
